Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1911 1
1923 1
1939 1
1944 2
1945 2
1946 2
1947 2
1948 1
1950 1
1951 2
1952 1
1953 1
1954 2
1955 1
1956 2
1957 2
1958 1
1960 1
1962 1
1963 3
1964 2
1965 3
1966 1
1967 5
1968 6
1969 1
1970 1
1971 7
1972 7
1973 6
1974 5
1975 3
1976 7
1977 4
1978 3
1979 10
1980 6
1981 13
1982 10
1983 3
1984 8
1985 3
1986 5
1987 15
1988 3
1989 8
1990 7
1991 2
1992 8
1993 7
1994 5
1995 8
1996 11
1997 11
1998 9
1999 11
2000 8
2001 7
2002 8
2003 3
2004 1
2005 4
2006 8
2007 12
2008 7
2009 6
2010 3
2011 4
2012 3
2013 9
2014 6
2015 3
2016 2
2017 6
2018 6
2019 5
2020 12
2021 11
2022 13
2023 7
2024 7
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

397 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
Cree BAC, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, She D, Rees W, Smith M, Cimbora D, Katz E, Bennett JL; N-MOmentum study investigators. Cree BAC, et al. Among authors: rees w. Lancet Neurol. 2024 Jun;23(6):588-602. doi: 10.1016/S1474-4422(24)00077-2. Lancet Neurol. 2024. PMID: 38760098 Clinical Trial.
Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial.
Bennett JL, Aktas O, Rees WA, Smith MA, Gunsior M, Yan L, She D, Cimbora D, Pittock SJ, Weinshenker BG, Paul F, Marignier R, Wingerchuk D, Cutter G, Green A, Hartung HP, Kim HJ, Fujihara K, Levy M, Katz E, Cree BAC; N-MOmentum study investigators. Bennett JL, et al. Among authors: rees wa. EBioMedicine. 2022 Dec;86:104321. doi: 10.1016/j.ebiom.2022.104321. Epub 2022 Nov 10. EBioMedicine. 2022. PMID: 36370634 Free PMC article. Clinical Trial.
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, Eichenfield LF, Forsha DW, Rees WC, Simpson EL, Spellman MC, Stein Gold LF, Zaenglein AL, Hughes MH, Zane LT, Hebert AA. Paller AS, et al. Among authors: rees wc. J Am Acad Dermatol. 2016 Sep;75(3):494-503.e6. doi: 10.1016/j.jaad.2016.05.046. Epub 2016 Jul 11. J Am Acad Dermatol. 2016. PMID: 27417017 Free article. Clinical Trial.
Multidisciplinary teams.
Rees W. Rees W. Br Med J. 1980 Jan 5;280(6206):50. doi: 10.1136/bmj.280.6206.50-a. Br Med J. 1980. PMID: 7357279 Free PMC article. No abstract available.
Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder.
Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, Fujihara K, Paul F, Cutter GR, Green AJ, Aktas O, Hartung HP, Lublin FD, Williams IM, Drappa J, She D, Cimbora D, Rees W, Smith M, Ratchford JN, Katz E, Cree BAC; N-MOmentum Study Investigators. Marignier R, et al. Among authors: rees w. Neurol Neuroimmunol Neuroinflamm. 2021 Mar 26;8(3):e978. doi: 10.1212/NXI.0000000000000978. Print 2021 May. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 33771837 Free PMC article. Clinical Trial.
397 results